A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients

Inclusion Criteria: * Adult patients, \>/= 18 years of age * HIV-1 infection * Currently treatment-naïve and eligible to initiate a ritonavir-boosted Protease Inhibitor based regimen and willing and able to initiate saquinavir/ritonavir therapy for the first 14 days; the saquinavir/ritonavir regimen will be in combination with two Nucleoside Reverse Transcriptase Inhibitors (NRTIs), in accordance with the current clinical HIV treatment guidelines * Body mass index 18-32 kg/m2, inclusive * Female patients of childbearing potential and male patients with female partners of childbearing potential must use 2 methods of contraception as defined by protocol during the study and for at least one month after the last dose of study drug * Non-smoker or patients who have stopped smoking more than three months prior to Day 1 of the study Exclusion Criteria: * Coinfection with hepatitis B or C (acute or chronic) * Anticipated use or need for significant concomitant medical treatment during the study period, other than background antiretroviral therapy * Participation in a clinical study with an investigational drug or device within 3 months prior to Day 1 of the study * Pregnant or lactating women * Any clinically relevant history of substance abuse or addiction including alcohol and/or other drugs of abuse * Special dietary restrictions that would prohibit consumption of standardized meal (e.g. vegetarian, vegan, gluten-free, lactose-free, kosher) * Decompensated liver disease * Congenital or documented acquired QT prolongation * Electrolyte disturbances, particularly uncorrected hypokalaemia * Clinically relevant bradycardia * Clinically relevant heart failure with reduced left-ventricular ejection fraction * Previous history of symptomatic arrhythmias * History of clinically significant gastro-intestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, , hematological, or allergic disease, metabolic disorder, cancer, or cirrhosis